Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Vampire bacteria has potential as living antibiotic

By R&D Editors | October 31, 2011

/sites/rdmag.com/files/legacyimages/RD/News/2011/10/VampireBacteria1.jpg

click to enlarge

The bacterium Micavibrio aeruginosavorus (yellow), attached to and leeching on a Pseudomonas aeruginosavorus bacterium (purple), surrounded by dead P. aeruginosavorus (gray) cells.

A
vampire-like bacteria that leeches onto specific other bacteria –
including certain human pathogens – has the potential to serve as a
living antibiotic for a range of infectious diseases, a new study
indicates.

The
bacterium, Micavibrio aeruginosavorus, was discovered to inhabit
wastewater nearly 30 years ago, but has not been extensively studied
because it is difficult to culture and investigate using traditional
microbiology techniques. However, biologists in the University of Virginia’s College of Arts & Sciences, Martin Wu and graduate student Zhang Wang, have decoded its genome and are learning “how it makes its living,” Wu said.

The
bacterium “makes its living” by seeking out prey—certain other
bacteria—and then attaching itself to its victim’s cell wall and
essentially sucking out nutrients. Unlike most other bacteria, which
draw nutrients from their surroundings, M. aeruginosavorus can survive
and propagate only by drawing its nutrition from specific prey bacteria.
This kills the prey—making it a potentially powerful agent for
destroying pathogens.

One
bacterium it targets is Pseudomonas aeruginosavorus, which is a chief
cause of serious lung infections in cystic fibrosis patients.

“Pathologists
may eventually be able to use this bacterium to fight fire with fire,
so to speak, as a bacterium that will aggressively hunt for and attack
certain other bacteria that are extremely harmful to humans,” Wu said.

His study, detailing the DNA sequence of M. aeruginosavorus, is published online in the journal BMC Genomics.
It provides new insights to the predatory lifestyle of the bacterium
and a better understanding of the evolution of bacterial predation in
general.

“We
used cutting-edge genomic technology in our lab to decode this
bacterium’s genome,” Wu said. “We are particularly interested in the
molecular mechanisms that allow it to hunt for and attack prey. This
kind of investigation would have been extremely difficult and expensive
to do only a few years ago.”

He
noted that overuse of traditional antibiotics, which work by either
inhibiting bacteria propagation or interfering with cell wall formation,
are creating so-called “super bugs” that have developed resistances to
treatment strategies. He suggests that new approaches are needed for
attacking pathogens without building up their resistance.

VampireBacteria2

Martin Wu (left) and Zhang Wang.

Additionally,
because M. aeruginosavorus is so selective a feeder, it is harmless to
the thousands of beneficial bacteria that dwell in the general
environment and in the human body.

“It
is possible that a living antibiotic such as M. aeruginosavorus—because
it so specifically targets certain pathogens—could potentially reduce
our dependence on traditional antibiotics and help mitigate the
drug-resistance problem we are now facing,” Wu said.

Another
benefit of the bacterium is its ability to swim through viscous fluids,
such as mucus. P. aeruginosavorus, the bacterium that colonizes the
lungs of cystic fibrosis patients, creates a glue-like biofilm,
enhancing its resistance to traditional antibiotics. Wu noted that the
living cells of M. aeruginosavorus can swim through mucus and biofilm
and attack P. aeruginosavorus.

M.
aeruginosavorus
also might have industrial uses, such as reducing
bacteria that form biofilms in piping, and for medical devices, such as
implants that are susceptible to the formation of biofilms.

Wu
said M. aeruginosavorus requires further study for a more thorough
understanding of its gene functions. He said genetic engineering would
be required to tailor the predatory attributes of the bacterium to
specific uses in the treatment of disease.

“We have a map now to work with, and we will see where it leads,” he said.

Wu
and Wang’s co-author is Daniel E. Kadouri, a researcher at the New
Jersey Dental School. Kadouri is interested in M. aeruginosavorus as an
agent for fighting oral biofilms, such as plaque.

SOURCE

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE